Sudeep Pharma Q3: Revenue Up, Profit & Margins Down Post-Listing

• Sudeep Pharma announced its September quarter results after its recent listing.
• Net profit declined by 6.15% year-on-year to ₹45.8 crore.
• Revenue showed strength, increasing by 9.3% to ₹162.7 crore.
• EBITDA and EBITDA margin both saw a decline compared to the previous year.
• Stock listed at ₹730, now at ₹686, but still 16% above its issue price.

Why It Matters: Sudeep Pharma's Q3 results show mixed performance; revenue grew, but profits and margins fell.